Cite
Blasi A, Saner F, Biancofiore G, et al. Comment to "Antithrombin III administration for portal vein thrombosis in patients with liver disease: A randomized double-blind controlled trial". Hepatol Res. 2018;48(3):E379-E380doi: 10.1111/hepr.12987.
Blasi, A., Saner, F., Biancofiore, G., & Lisman, T. (2018). Comment to "Antithrombin III administration for portal vein thrombosis in patients with liver disease: A randomized double-blind controlled trial". Hepatology research : the official journal of the Japan Society of Hepatology, 48(3), E379-E380. https://doi.org/10.1111/hepr.12987
Blasi, Annabel, et al. "Comment to "Antithrombin III administration for portal vein thrombosis in patients with liver disease: A randomized double-blind controlled trial"." Hepatology research : the official journal of the Japan Society of Hepatology vol. 48,3 (2018): E379-E380. doi: https://doi.org/10.1111/hepr.12987
Blasi A, Saner F, Biancofiore G, Lisman T. Comment to "Antithrombin III administration for portal vein thrombosis in patients with liver disease: A randomized double-blind controlled trial". Hepatol Res. 2018 Feb;48(3):E379-E380. doi: 10.1111/hepr.12987. PMID: 28975687.
Copy
Download .nbib